148 related articles for article (PubMed ID: 18332874)
1. Metallothionein 1G acts as an oncosupressor in papillary thyroid carcinoma.
Ferrario C; Lavagni P; Gariboldi M; Miranda C; Losa M; Cleris L; Formelli F; Pilotti S; Pierotti MA; Greco A
Lab Invest; 2008 May; 88(5):474-81. PubMed ID: 18332874
[TBL] [Abstract][Full Text] [Related]
2. Metallothionein 1G functions as a tumor suppressor in thyroid cancer through modulating the PI3K/Akt signaling pathway.
Fu J; Lv H; Guan H; Ma X; Ji M; He N; Shi B; Hou P
BMC Cancer; 2013 Oct; 13():462. PubMed ID: 24098937
[TBL] [Abstract][Full Text] [Related]
3. Quantitative assessment of RASSF1A methylation as a putative molecular marker in papillary thyroid carcinoma.
Kunstman JW; Korah R; Healy JM; Prasad M; Carling T
Surgery; 2013 Dec; 154(6):1255-61; discussion 1261-2. PubMed ID: 24383114
[TBL] [Abstract][Full Text] [Related]
4. RASSF10 is Epigenetically Inactivated and Suppresses Cell Proliferation and Induces Cell Apoptosis by Activating the p53 Signalling Pathway in Papillary Thyroid Carcinoma Cancer.
Fan C; Wang W; Jin J; Yu Z; Xin X
Cell Physiol Biochem; 2017; 41(3):1229-1239. PubMed ID: 28268222
[TBL] [Abstract][Full Text] [Related]
5. LDOC1 inhibits proliferation and promotes apoptosis by repressing NF-κB activation in papillary thyroid carcinoma.
Zhao S; Wang Q; Li Z; Ma X; Wu L; Ji H; Qin G
J Exp Clin Cancer Res; 2015 Dec; 34():146. PubMed ID: 26637328
[TBL] [Abstract][Full Text] [Related]
6. Hypermethylation, but not LOH, is associated with the low expression of MT1G and CRABP1 in papillary thyroid carcinoma.
Huang Y; de la Chapelle A; Pellegata NS
Int J Cancer; 2003 May; 104(6):735-44. PubMed ID: 12640681
[TBL] [Abstract][Full Text] [Related]
7. Metallothionein Isoform Expression in Benign and Malignant Thyroid Lesions.
Wojtczak B; Pula B; Gomulkiewicz A; Olbromski M; Podhorska-Okolow M; Domoslawski P; Bolanowski M; Daroszewski J; Dziegiel P
Anticancer Res; 2017 Sep; 37(9):5179-5185. PubMed ID: 28870952
[TBL] [Abstract][Full Text] [Related]
8. DKK3 is a potential tumor suppressor gene in papillary thyroid carcinoma.
Yin DT; Wu W; Li M; Wang QE; Li H; Wang Y; Tang Y; Xing M
Endocr Relat Cancer; 2013 Aug; 20(4):507-14. PubMed ID: 23702469
[TBL] [Abstract][Full Text] [Related]
9. The expression and role of serum response factor in papillary carcinoma of the thyroid.
Kim HJ; Kim KR; Park HS; Jang KY; Chung MJ; Shong M; Moon WS
Int J Oncol; 2009 Jul; 35(1):49-55. PubMed ID: 19513551
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of HIF-1α, metallothionein and SLUG is associated with high TNM stage and lymph node metastasis in papillary thyroid carcinoma.
Wang N; Dong CR; Jiang R; Tang C; Yang L; Jiang QF; Chen GG; Liu ZM
Int J Clin Exp Pathol; 2014; 7(1):322-30. PubMed ID: 24427353
[TBL] [Abstract][Full Text] [Related]
11. Gene expression profile analyze the molecular mechanism of CXCR7 regulating papillary thyroid carcinoma growth and metastasis.
Zhang H; Teng X; Liu Z; Zhang L; Liu Z
J Exp Clin Cancer Res; 2015 Feb; 34(1):16. PubMed ID: 25887589
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic regulation of Wnt signaling pathway gene SRY-related HMG-box 17 in papillary thyroid carcinoma.
Li JY; Han C; Zheng LL; Guo MZ
Chin Med J (Engl); 2012 Oct; 125(19):3526-31. PubMed ID: 23044318
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the novel tumor-suppressor gene CCDC67 in papillary thyroid carcinoma.
Yin DT; Xu J; Lei M; Li H; Wang Y; Liu Z; Zhou Y; Xing M
Oncotarget; 2016 Feb; 7(5):5830-41. PubMed ID: 26716505
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of metallothionein 1F, a putative oncosuppressor, by loss of heterozygosity in colon cancer tissue.
Yan DW; Fan JW; Yu ZH; Li MX; Wen YG; Li DW; Zhou CZ; Wang XL; Wang Q; Tang HM; Peng ZH
Biochim Biophys Acta; 2012 Jun; 1822(6):918-26. PubMed ID: 22426038
[TBL] [Abstract][Full Text] [Related]
15. Caveolin-1 expression in papillary thyroid carcinoma: correlation with clinicopathological parameters and BRAF mutation status.
Paskaš S; Janković J; Marečko I; Išić Denčić T; Tatić S; Cvejić D; Savin S
Otolaryngol Head Neck Surg; 2014 Feb; 150(2):201-9. PubMed ID: 24255086
[TBL] [Abstract][Full Text] [Related]
16. Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are up-regulated in papillary thyroid carcinoma: a cDNA and tissue microarray study.
Wasenius VM; Hemmer S; Kettunen E; Knuutila S; Franssila K; Joensuu H
Clin Cancer Res; 2003 Jan; 9(1):68-75. PubMed ID: 12538453
[TBL] [Abstract][Full Text] [Related]
17. TIMP3 regulates migration, invasion and in vivo tumorigenicity of thyroid tumor cells.
Anania MC; Sensi M; Radaelli E; Miranda C; Vizioli MG; Pagliardini S; Favini E; Cleris L; Supino R; Formelli F; Borrello MG; Pierotti MA; Greco A
Oncogene; 2011 Jul; 30(27):3011-23. PubMed ID: 21339735
[TBL] [Abstract][Full Text] [Related]
18. MiR-20b Displays Tumor-Suppressor Functions in Papillary Thyroid Carcinoma by Regulating the MAPK/ERK Signaling Pathway.
Hong S; Yu S; Li J; Yin Y; Liu Y; Zhang Q; Guan H; Li Y; Xiao H
Thyroid; 2016 Dec; 26(12):1733-1743. PubMed ID: 27717302
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of 14q32-encoded miRNAs and tumor suppressor role for miR-654-3p in papillary thyroid cancer.
Geraldo MV; Nakaya HI; Kimura ET
Oncotarget; 2017 Feb; 8(6):9597-9607. PubMed ID: 28030816
[TBL] [Abstract][Full Text] [Related]
20. Discriminatory miRNAs for the Management of Papillary Thyroid Carcinoma and Noninvasive Follicular Thyroid Neoplasms with Papillary-Like Nuclear Features.
Jahanbani I; Al-Abdallah A; Ali RH; Al-Brahim N; Mojiminiyi O
Thyroid; 2018 Mar; 28(3):319-327. PubMed ID: 29378472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]